Vyriad: Vyriad, Inc. Announces Strategic Collaboration with Novartis to Develop in Vivo CAR-T Cell Therapies

Vyriad, Inc. announced a strategic collaboration with Novartis to discover and develop in vivo chimeric antigen receptor (CAR) T-cell therapies. The collaboration will leverage Vyriad's active targeting lentiviral vector platform and Novartis expertise and leadership in cell therapy innovation. Novartis and Vyriad will focus on the identification and development of in vivo CAR-T cell therapy candidates to be clinically advanced by Novartis. Vyriad will receive an upfront payment, milestone payments, and tiered royalties on each program. Vyriad's targeted lentiviral vector platform provides T-cell specificity and activation in vivo, enabling delivery of CAR payloads to T cells in their natural environment. Through its viral vector engineering acumen, Vyriad developed a lentiviral delivery system with the potential to target and transduce resting T cells and program them while still inside the body to become potential treatments for patients.